Immunic, inc. reports year end 2022 financial results and provides corporate update

– initial results from ongoing part c of phase 1 clinical trial of imu-856 in celiac disease expected mid-2023 – – interim results from phase 2 calliper trial of vidofludimus calcium in progressive multiple sclerosis expected in the second half of 2023 – – $116.4 million in cash, cash equivalents and investments expected to fund immunic into the fourth quarter of 2024 – – webcast to be held today, february 23, 2023, at 8:00 am et – new york , feb. 23, 2023 /prnewswire/ -- immunic , inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the year ended december 31, 2022, and provided a corporate update. "we made significant progress throughout the year in advancing our lead asset, vidofludimus calcium, for the treatment of multiple sclerosis (ms).
IMUX Ratings Summary
IMUX Quant Ranking